Monitor for imminent ATM or registered direct offering announcements, which would likely cause share price pressure due to dilution. The company's survival depends on successful capital raises, making it highly sensitive to market conditions and investor sentiment.
Price Chart
Executive Summary
Elicio Therapeutics filed an S-3/A amendment to update its shelf registration, enabling future public offerings of up to $200 million in securities. This filing signals potential capital raising, likely through an at-the-market (ATM) program, to fund operations amid substantial doubt about its ability to continue as a going concern.
Key Financial Metrics
Key Facts
- Filed S-3/A shelf registration allowing future issuance of up to $200 million in securities including common stock, preferred stock, debt, and warrants.
- Company has $20.6 million in cash as of September 30, 2025, with net losses of $31.9 million over the past nine months.
- Management states there is substantial doubt about the company's ability to continue as a going concern, with cash expected to last only through Q2 2026.
- Recent financings have been dominated by related-party transactions with GKCC, including a $10 million promissory note in June 2025.
- Market cap is $227 million, meaning a full $200 million offering would represent significant potential dilution.
Financial Impact
Up to $200 million in potential dilutive offerings, representing approximately 88% of current market cap.
Risk Factors
- Significant shareholder dilution from future offerings
- Continued reliance on related-party financing from GKCC
- Risk of delisting if unable to maintain Nasdaq listing requirements
- Failure to raise capital could lead to severe operational cuts or insolvency
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001628280-26-013187 |
| Document: 0001628280-26-013187-index-headers.html | 0001628280-26-013187 |
| Document: 0001628280-26-013187-index.html | 0001628280-26-013187 |
| Document: 0001628280-26-013187.txt | 0001628280-26-013187 |
| CONTEXT: 10-Q (2025-11-13) | 0001601485-25-000124 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | DEF 14A | $1.88 | awaiting T+60 | — | $1.66 (−11.70%) |
Sep 22, 2026 4w ago | Institutional Cluster | $1.87 | awaiting T+60 | — | $1.66 (−11.23%) |
Jul 2, 2026 16w ago | 424B5 | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.66 (+48.45%) |
Jul 2, 2026 16w ago | 8-K | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.66 (+48.45%) |
Jun 24, 2026 17w ago | 8-K | $3.75 $1.89 | ▼ −49.60% | ▼ −53.33% | $1.66 (−55.73%) |
Jun 17, 2026 18w ago | 8-K | $4.71 $2.05 | ▼ −56.48% | ▼ −59.62% | $1.66 (−64.76%) |
May 11, 2026 24w ago | 8-K | $10.55 $3.14 | ▼ −70.24% | ▼ −74.62% | $1.66 (−84.27%) |
Mar 17, 2026 32w ago | EFFECT | $12.18 $14.20 | ▲ +16.58% | ▲ +6.72% | $1.66 (−86.37%) |
Mar 12, 2026 32w ago | Press Release | $12.20 $13.55 | ▲ +11.07% | ▼ −0.55% | $1.66 (−86.39%) |
Mar 2, 2026 34w ago | S-3/A | $12.50 $10.77 | ▲ +13.84% | ▲ +24.16% | $1.66 (+86.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers